Communiqués Aditxt, Inc.

Actions

ADTX

US0070258696

Recherche biotechnologique et médicale

Temps Différé OTC Markets Autres places de cotation 20:28:57 05/08/2026			Varia. 5j.	Varia. 1 janv.
0,002800 ^USD	-1,41%		-6,67%	-100,00%

17/06	Les plus fortes baisses en avant-Bourse	MT
12/06	Les plus fortes hausses en avant-Bourse	MT

Communiqués

09/06	Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million	BU
08/06	Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection	BU
02/06	Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer, Founder and Former CEO of $1B NYSE Enterprise Which Delivered 8.5% Dividends to Shareholders	AQ
01/06	Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders	BU
14/05	Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026	BU
20/04	Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients	BU
19/03	Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer	BU
13/03	Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection	BU
05/03	Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026	BU
20/11	Aditxt : Audit Committee Charter (Aditxt Audit Committee Charter Effective 11.19.25)	PU
19/11	Aditxt Provides Updates on its Growth Vision for bitXbio, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing	AQ
18/11	Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta’s Planned IPO, And Evofem’s Plan to Regain a National Listing	BU
29/10/25	Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025	BU
27/10/25	Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market	BU
20/10/25	Evofem Announces Voting Results from Special Meeting of Stockholders	PR
11/09/25	Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms	PR
09/09/25	Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting	PR
26/08/25	Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030	AQ
25/08/25	Aditxt’s Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030	BU
21/08/25	Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law	PR
12/08/25	Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio Initiative	AQ
11/08/25	Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative	BU
05/08/25	Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference	PR
29/07/25	Aditxt’s Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases	BU
25/07/25	Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic(R) Ovarian Test	AQ